Table 2.
Alterations in Functional Respiratory Imaging Endpoints Measured Using HRCT
| Endpoint | Parameter | Region | Placebo (Baseline vs D28, Treatment Ratio (95% Cr I)) | Nemiralisib (Baseline vs D28, Treatment Ratio (95% Cr I)) | Nemiralisib vs Placebo (Baseline vs D28, Treatment Ratio (95% Cr I)) | Probability (θ>1) or (θ<1)a |
|---|---|---|---|---|---|---|
| siVaw | Specific Imaging Airway Volume | Distal | 1.01 (0.83, 1.24) | 1.00 (0.83, 1.20) | 0.98 (0.75, 1.30) | 45.2% |
| siRaw | Specific imaging airway resistance | Distal | 0.97 (0.53, 1.77) | 1.13 (0.63, 2.02) | 1.17 (0.51, 2.72) | 35.6% |
| siVaww | Specific airway wall thickness | Distal | 0.96 (0.88, 1.06) | 0.92 (0.84, 1.00) | 0.95 (0.83, 1.09) | 77.1% |
| LAS | Low attenuation score | Total | 1.01 (0.84, 1.21) | 0.98 (0.83, 1.17) | 0.97 (0.75, 1.26) | 58.6% |
| IALD | Internal airflow lobar distribution | Upper | 1.03 (0.98, 1.09) | 0.99 (0.94, 1.04) | 0.96 (0.89, 1.03) | 59.7% |
| Lower | 0.98 (0.93, 1.02) | 0.99 (0.95, 1.04) | 1.02 (0.95, 1.09) | 97.9% | ||
| BVD | Blood vessel density | Total | 0.95 (0.88, 1.03) | 0.94 (0.88, 1.01) | 0.99 (0.89, 1.10) | 44.4% |
Note: aθ represents the true treatment ratio to placebo.
Abbreviations: BVD, blood vessel density; Cr l, credible interval; D28, day 28; HRCT, high resolution computed tomography; IALD, internal airflow lobar distribution; LAS, low attenuation score; siRaw, specific imaging airway resistance; siVaw, specific imaging airway volume; siVaww, specific imaging airway wall thickness.